Prostaglandin E1 suppresses tumor necrosis factor-alpha and interleukin-10 production by lipopolysaccharides-stimulated mononuclear cells.
Prostaglandin E1 has been clinically used in a variety of vascular occlusive diseases. We investigated the in vitro effect of prostaglandin E1 on the synthesis of tumor necrosis factor-alpha, interleukin-1, interleukin-6, interleukin-10 and transforming growth factor beta by human peripheral blood mononuclear cells stimulated with lipopolysaccharides. Prostaglandin E1 significantly suppressed both the mRNA expression and the production of tumor necrosis factor-alpha and interleukin-10 by lipopolysaccharides-stimulated peripheral blood mononuclear cells in a dose-dependent manner (1 x 10(-6)-1 x 10(-8) M). Since tumor necrosis factor-alpha is a potent proinflammatory cytokine involved in certain inflammatory diseases, our findings suggest the possibility to expand the clinical application of prostaglandin E1.
Ishikawa
O
O
Department of Dermatology, Gunma University School of Medicine, Maebashi, Japan. osamuish@sb.gunma-u.ac.jp
Kubota
Y
Y
Miyachi
Y
Y
D000328:Adult; D000527:Alprostadil / Q000494:pharmacology*; D006801:Humans; D066298:In Vitro Techniques; D016753:Interleukin-10 / Q000096:biosynthesis* / Q000235:genetics; D007963:Leukocytes, Mononuclear / Q000187:drug effects* / Q000378:metabolism; D008070:Lipopolysaccharides / Q000494:pharmacology*; D008297:Male; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis* / Q000235:genetics
D008070:Lipopolysaccharides; D012333:RNA, Messenger; D014409:Tumor Necrosis Factor-alpha; D016753:Interleukin-10; D000527:Alprostadil